Riskpilot← Back to searchSign inGet full accessICEPHARMA A/S
A/SActiveCVR 36393459Høje Taastrup Boulevard 53Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20145 employeeswww.icepharma.dk
Revenue 2024
DKK -410K
-81% vs 2023
EBITDA margin
869.0%
+35% vs 2023
Equity ratio
73.8%
Financial strength
Net profit 2024
DKK -3,6M
+34% vs 2023
| Revenue | DKK -410K | -81% |
| EBITDA | DKK -3,6M | +35% |
| Net profit | DKK -3,6M | +34% |
| Total assets | DKK 5,1M | +8% |
| Equity | DKK 3,7M | +68% |
| Employees | 5 | — |
Legal name
ICEPHARMA A/S
CVR number
36393459
Legal form
Aktieselskab
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
30. september 2014
Share capital
DKK 500.000
Employees
5 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter samt al virksomhed, som efter bestyrelsens skøn er beslægtet hermed.
Address
Høje Taastrup Boulevard 53
Phone
+4522150409
Email
info@icepharma.dk
Website
www.icepharma.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 434 | 2.184 | -722 | -3.628 | -3.926 | -2.207 | -2.436 | -1.026 | -2.176 | -410 |
| Staff expenses | -4.952 | -5.930 | -4.119 | -3.439 | -3.762 | -3.450 | -2.994 | -3.685 | -3.267 | -3.152 |
| EBITDA | 434 | -3.746 | -4.841 | -7.068 | -7.688 | -5.658 | -5.430 | -4.711 | -5.443 | -3.562 |
| Depreciation & amort. | -4.952 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -4.518 | -3.746 | -4.841 | -7.068 | -7.688 | -5.658 | -5.430 | -4.711 | -5.443 | -3.562 |
| Net financials | -1 | -24 | -6 | -7 | -2 | -2 | 6 | -37 | -12 | -1 |
| Profit before tax | -4.519 | -3.770 | -4.847 | -7.074 | -7.690 | -5.660 | -5.424 | -4.748 | -5.455 | -3.563 |
| Tax | -0 | -0 | -0 | 161 | -0 | -0 | -0 | -0 | -27 | -0 |
| Net profit | -4.519 | -3.770 | -4.847 | -7.235 | -7.690 | -5.660 | -5.424 | -4.748 | -5.428 | -3.563 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 836 | 1.541 | 598 | 2.113 | 1.751 | 1.834 | 2.916 | 3.502 | 4.714 | 5.077 |
| Equity | -673 | 188 | -579 | 829 | 581 | 7 | 690 | 1.648 | 2.231 | 3.745 |
| Long-term debt | 0 | 0 | 0 | 0 | 135 | 0 | 293 | 303 | 313 | 0 |
| Short-term debt | 1.509 | 1.353 | 1.177 | 1.285 | 1.035 | 1.827 | 1.933 | 1.550 | 2.171 | 1.332 |
| Total debt | 1.509 | 1.353 | 1.177 | 1.285 | 1.170 | 1.827 | 2.226 | 1.854 | 2.484 | 1.332 |
EBITDA margin
-356192700.0%
This company
15.8%
Market median
-2254384277% vs market
20152024
Equity ratio
73.8%
This company
38.2%
Market median
+93% vs market
20152024
Return on equity
-95.1%
This company
18.4%
Market median
-617% vs market
20152024
Net profit margin
-356254300.0%
This company
8.1%
Market median
-4398201335% vs market
20152024
Asset turnover
-0.08×
This company
1.12×
Market median
-107% vs market
20152024
Debt / equity
0.36×
This company
0.62×
Market median
+42% vs market
20152024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-09-30 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
HÞ Management | Management | 2016 | — | — |
PP Management | Management | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2017 | — | — | |
| Board of Directors | 2014 | — | — | |
| Chairman | 2014 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2014 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ICEPHARMA A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Hörður Þórhallsson | Management | 0 companies |
| Peter Popowicz | Management | 0 companies |
| Margrét Guðmundsdóttir | Board of Directors | 0 companies |
| Petrea Ingileif Gudmundsdottir | Board of Directors | 0 companies |
| Jóhann Ingi Kristjánsson | Board of Directors | 0 companies |
| Bessi Húnfjörð Jóhannesson | Board of Directors | 0 companies |
| Kristján Johannsson | Chairman | 0 companies |